Advanced searches left 3/3

Metastatic Melanoma BRAF - Crossref

Summarized by Plex Scholar
Last Updated: 22 May 2022

* If you want to update the article please login/register

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma

With separate triggers and different response styles, the combination of targeted agents and immunotherapy to treat patients with BRAF V600-mutant melanoma can potentially enhance patient outcomes. In comparison to petraceutic or unresectable locally advanced BRAF V600-mutant melanoma in treatment-naive patients with metastatic or unresponsive locally advanced BRAF V600-mutant melanoma.

Source link: https://doi.org/10.2217/fon-2021-1486


Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

PURPOSE PREDICTION The combination of an anti-programmed death receptor 1 antibody plus dabrafenib and trametinib has higher antitumor activity in comparison to dabrafenib plus trametinib alone, according to preclinical results. These findings are backed up by translational findings showing that immune checkpoint inhibitors plus targeted therapy can improve treatment outcomes in patients with BRAF V600–mutant metastatic melanoma. Comparing placebo plus dabrafenib and trametinib in patients with BRAF V600-mutant unresectable or metastatic melanoma, the COMBI-i is a phase III trial comparing spartalizumab, an anti-programmed death receptor 1 antibody, in combination with dabrafenib and trametinib. Patients received spartalizumab 400 mg intravenously every four weeks, whereas trametinib 2 mg orally every 4 weeks, or placebo-DabTram. In 55% of patients in the sparta-DabTram arm and 33% in the placebo-DabTram arm, and 33% in the placebo-DabTram group, as described above.

Source link: https://doi.org/10.1200/jco.21.01601


The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study

Patients with BRAFV600-mutant metastatic melanoma have been greatly improved in the treatment landscape of patients with BRAFV600-mutant metastatic melanoma and BRAF/MEK-directed targeted therapy. Although TT allows for rapid disease control, the growth of secondary TT resistance limits the duration of responses. According to the first and second-line therapy, respectively, 135 patients with BRAF-mutated, metastatic melanoma with TT followed by CPI for consecutive treatment. Patients receiving front-line CPI received significantly higher objective response rates to second-line drugs, according to studies. Our results showed that rapid disease progression was less prevalent in patients receiving front-line CPI, and that subsequent therapy with TT resulted in improved survival rates. In a subgroup of previously untreated BRAF-mutant metastatic melanoma patients, sequential therapy with front-line CPI is associated with improved tumor control and overall survival.

Source link: https://doi.org/10.3390/cancers14092082


Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis

Based on the pooled risk ratios and 95% credible intervals, we gathered data on the cumulative incidence of any-grade AEs, which results in grades 1-5 AEs and severe AEs. The acceptability of combined dabrafenib and trametinib for any-grade AEs is superior to the combination of vemurafenib and cobimetinib. Moreover, nivolumab combined with ipilimumab raises any-grade AEs more often than single-agent ipilimumab or nivolumab. Dabrafenib has the highest acceptability among severe AEs, unlike single-agent vemurafenib or encorafenib. In combination with binimetinib and a combination of vemurafenib and cobimetinib, the ranking of vemurafenib and cobimetinib is superior to encorafenib and cobimetinib are superior to encorafenib and a blend of vemurafenib and cobimetinib makes it superior to encorencorafenib and binib and binib and afenib and cobimetinib and cobimetinib and cobimetinib and cobimetinib and c in combination of c cenib and c cenib and c enib and c enib and c in combination c cibimetinib and cobimetinib and cobimetinib and cobimetinib and cobimetinib cobimet BRAF V600-mutant melanoma patients' lowest AE risk therapy options were found by us, according to our researchers. Moreover, single-agent dabrafenib can be used as the first option in monotherapy, and a combination of dabrafenib and trametinib is the most common combination therapy.

Source link: https://doi.org/10.3389/fonc.2022.865656

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions